1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

FDA-EMA Parallel Scientific Advice Program For Complex Generics Could Add Health Canada

 
• By Derrick Gingery

Preliminary discussions are ongoing about adding Health Canada to the program intended to foster streamlined complex generic approval and increase access.

Canada, USA, EU flags
The FDA-EMA parallel scientific advice program could gain more interest from industry if Health Canada joins the group. • Source: Shutterstock

The FDA-EMA parallel scientific advice (PSA) program for complex generics soon could add another regulator, which may increase the appeal of the meeting process intended to streamline patient access to the products.

Health Canada is interested in joining the group, which would make the trilateral PSA meetings (US Food and Drug Administration, European Medicines

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.